Article Text
Abstract
INTRODUCTION
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is uncommon but important. It can be disabling but is usually treatable, and probably underdiagnosed. The only population-based studies suggest a prevalence of one or two per 100 000 but these are probably underestimates because of lack of referral or recognition of cases (Lunn et al. 1999; McLeod et al. 1999). In our population-based study of 46 patients in the south-east of England, 13% required an aid to walk and 54% were receiving medical treatment on the prevalence date (Lunn et al. 1999). The natural history of untreated disease is not known but two old large series included 7–35% of patients who eventually became bedridden or died from their disease (Dyck et al. 1975; Prineas & McLeod 1976). In a more recent large series, improvement with treatment was only partial, relapses were frequent, and 60% of patients were left with disability or continued
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England
- Chronic inflammatory demyelinating polyradiculoneuropathy in solid organ transplant recipients: a prospective study
- CIDP: mimics and chameleons
- Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database
- CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS
- MRI of the cervical nerve roots in the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy: a single-institution, retrospective case–control study
- Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy
- Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy
- Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype
- Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP